Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed that approximately 25% of patients experienced hair loss after COVID-19 infection, with nonscarring alopecia being the most common form.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This article reviews age-related changes in facial structure at a cellular level and summarizes potential solutions for rejuvenation surgery, but reports no new clinical results.

This study found that minoxidil absorption through the skin increased with longer contact times, reaching over 75% of the maximum absorption within four hours.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

Minoxidil activation by hair enzymes predicts treatment success for female hair loss.

In this study, a low concentration zinc sulphate solution was investigated for managing recurrent herpes simplex infections, but no new clinical results were reported.

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

This study found that low-dose oral minoxidil was more effective than topical minoxidil in increasing hair density and patient satisfaction among men with androgenetic alopecia, with fewer local side effects and better compliance reported over six months.

This study found that magistral topical minoxidil solutions had differences in color, viscosity, and acidity compared to industrial formulations and issues with drug content and dosage indication, despite similar follicular penetration.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.

This review outlines the oral toxic effects of chemotherapy and stresses the need for evaluating dental health prior to treatment to mitigate these complications, but it reports no new clinical results.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

This abstract describes monilethrix, an autosomal dominant genodermatosis with symptoms like hair fragility and keratosis pilaris, and does not report new experimental results.

This study found that oral minoxidil showed limited cosmetic effectiveness in treating severe alopecia areata, with only 18% of patients experiencing a noticeable response.

In this study, oral zinc sulphate was found to cause hair hypopigmentation and significantly inhibit eumelanogenesis in mice.

This study found that coadministering minoxidil with tretinoin cream increased minoxidil absorption nearly threefold in healthy males, attributed to increased stratum corneum permeability.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.

This study found that oral retinoid therapy may provide clinical improvement in a small percentage of patients with treatment-resistant lichen planopilaris, although it is not commonly used as a first-line treatment.